IGF-1 LR3

3D structure not available for this compound.

Sequence

Mechanism of Action

IGF-1 LR3 is a modified analogue of insulin-like growth factor-1, engineered with a Glu3→Arg substitution and a 13-residue N-terminal extension that markedly reduces binding to IGF-binding proteins and extends bioavailability relative to native IGF-1. It binds and activates the IGF-1 receptor, triggering downstream PI3K/Akt and MAPK/ERK signaling studied in relation to cellular proliferation, protein synthesis, and anabolic tissue signaling.

IGF-1 receptor (IGF-1R)

Research Literature

Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets

Animal Study

Journal of Developmental Origins of Health and Disease · 2023

Acute IGF-1 LR3 infusion into late-gestation fetal sheep suppressed glucose-stimulated insulin secretion in vivo, but isolated islets from treated animals retained normal secretory capacity, indicating a transient extrinsic effect rather than lasting beta-cell damage.

View Source →

N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling

In Vitro

International Journal of Molecular Sciences · 2022

Using IGF-1 LR3 as the receptor-activating ligand, glycosylation-deficient cells showed reduced surface IGF-1R and blunted ERK1/2 phosphorylation, identifying N-linked glycosylation as required for normal IGF-1R/ERK signaling.

View Source →